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ABSTRACT 
We genotyped the androgen receptor (AR) 
gene in 31 Australasian patients with androgen 
insensitivity syndrome (AIS). The entire coding 
region of AR was examined including analysis of 
polymorphic CAG and GGN repeats in all 
patients. AR defects were found in 66.7% (6/9) 
of patients with complete AIS (CAIS) and 13.6% 
(3/22) of patients with partial AIS (PAIS). A 
novel deletion (N858delG) leading to a pre-
mature stop codon was found in CAIS patient 
PI. CAIS patient P2 has a novel deletion 
(N2676delGAGT) resulting in a stop at codon 
787. These mutations would result in inactiva-
tion of AR protein. A novel insertion of a 
cysteine residue in the first zinc finger of the AR 
DNA-binding domain (N2045_2047dupCTG) was 
found in CAIS patient P3. PAIS patient P4 has a 
novel amino acid substitution (Arg760Ser) in the 
AR ligand binding domain, which may impair 
ligand binding. Five patients were found to have 
previously reported AR mutations and no 
mutations were identified in the remaining 
patients. 
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INTRODUCTION 
Androgen insensitivity syndrome (AIS) (inci-
dence 1:20,000-64,000 male births) is an X-linked 
recessive disorder occurring in individuals with an 
XY karotype and varying degrees of impaired male 
genital development. Complete AIS (CAIS) is 
characterised by a complete absence of virilisation. 
Affected individuals have female external genitalia 
and breast development. Partial AIS (PAIS) com-
prises a wide phenotypic spectrum ranging from 
perineoscrotal hypospadias, bifid scrotum, and 
cryptorchidism, to marked undervirilisation inclu-
ding clitoromegaly and labio-scrotal fusion. 
During embryogenesis androgens are critical for 
the virilisation of Wolffian duct structures and 
external genitalia. Androgen action is mediated by 
the androgen receptor (AR), a nuclear transcription 
factor. AR is encoded by a single copy gene located 
on a highly conserved region of the X chromosome 
(Xqll-12)1. AR mutations are the molecular cause 
of androgen insensitivity. Mutations have been 
identified throughout the coding region of the AR 
gene2. 
The AR is a member of the nuclear receptor 
family. Binding of androgen to the AR induces a 
conformational change that facilitates receptor 
dimerization, nuclear transport and interaction with 
target DNA, culminating in regulation of target 
gene transcription3. AR consists of three major 
functional regions, comprising the amino-terminal 
transactivation domain (TAD), a DNA-binding 
domain (DBD), and the carboxyl-terminal ligand-
binding domain (LBD)34. Protein-protein inter-
actions between domains and with co-regulatory 
proteins are also important in AR function. 
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Identification of AR mutations in patients with AIS, 
and in vitro molecular studies evaluating the 
functional effect of mutant AR for genotype/ 
phenotype correlations are crucial for under-
standing this condition. 
The TAD of the AR gene contains two poly-
morphic trinucleotide repeat regions. The glutamine 
(Gin) repeat region consists of a length of tri-
nucleotide repeats located towards the 5' end of 
exon A; (CAG)x CAA, χ = #CAG, mean #CAG = 
21, range #CAG = 9-38 (Caucasians)5"7. The 
glycine (Gly) repeat region consists of trinucleotide 
repeats located towards the 3' of exon A; (GGN)^ 
or [(GGT)3 GGG (GGT)2 (GGC)x], * = #GGC, y = 
#GGN, mean #GGN = 22, range #GGN = 10-31 
(Caucasians)8"10. 
Abnormal expansion of the Gin repeat leads to 
X-linked spinal muscular dystrophy (SBMA), a 
neuromuscular disease associated with endocrino-
logical abnormalities such as low virilisation, oligo-
spermia or azoospermia, and testicular atrophy". 
All patients with SBMA have an expanded Gin 
repeat (range 40-62 repeats)12, and some patients 
show clinical signs of PAIS including elevated 
testosterone and/or LH levels13. The degree of 
endocrine dysfunction in SBMA is correlated with 
the number of Gin repeats13. 
It has also been shown that normal polymorphic 
size variation of the Gin repeat region is associated 
with undermasculinisation , male infertility9'14"17, 
benign prostatic hypeiplasia18, prostate cancer5'19 
and endometrial cancer0. Normal polymorphic size 
variation of the Gly repeat is also associated with 
disease. Sasaki et al. report an increased risk of 
endometrial cancer with increased Gly repeats 
(GGC>17)21, and there are reports of an association 
between prostate cancer and short Gly repeats 
(GGC<16)5'19'22. Some studies on the joint distribu-
tion of Gin and Gly repeats in male infertility23 
prostate cancer5,22,24 and esophageal cancer25 have 
been undertaken with no obvious trends in the data. 
AR genotyping is important clinically. Charac-
terisation of the molecular mechanisms of AR 
dysfunction is helpful in directing hormonal 
therapy. For example, the mutation Met807Thr 
disrupts testosterone binding of the receptor to a 
greater extent than dihydrotestosterone (DHT)26. 
Thus a patient with this mutation responds 
favourably to DHT treatment. This finding has been 
used to restore male genital development in an 
infant with PAIS4,26. Identification of AR mutations 
and characterisation of the inheritance of the 
mutant allele provide valuable information for 
genetic counselling of affected families. 
We have used the method of genomic DNA 
PCR sequencing to analyse the AR genes of 31 
patients with a provisional diagnosis of AIS. The 
31 patients with AIS were referred from paediatric 
endocrinologists across Australia. As part of the 
study, we examined the length of the Gin repeat 
region in order to examine the role of AR Gin 
repeats in AIS. Gin repeat regions in family 
members were also examined in order to determine 
the pattern of inheritance of the mutant AR allele. 
We report here the spectrum of mutations identified 
in a large Australian cohort with clinical features 
consistent with AIS. 
METHODS 
Patients 
All patients were genotyped by the Mater 
Molecular Genetics Laboratory, Mater Pathology, 
Mater Misericordia Hospital, South Brisbane, QLD. 
The Mater Molecular Genetics Laboratory is acc-
redited by the National Australia Testing Authority 
(NATA). Patient genotyping by the Mater Mole-
cular Genetics Laboratory was approved by the 
Mater Health Services Human Research Ethics 
Committee (MHSHREC). All patients undergo 
testing as part of routine clinical diagnosis and 
assessment; clinicians obtain consent from patients 
prior to genetic testing. 
Eleven patients with a provisional diagnosis of 
CAIS and 23 patients with a provisional diagnosis 
of PAIS were referred to our diagnostic service for 
detection of AR gene mutations (Table 1, patients 
PI to P31). All patients were Caucasians from 
various regions of Australasia and were referred 
over a period of approximately 8 years from 1996 
to 2004. At that time we were not aware of any 
other Australian diagnostic service performing AR 
genotyping in cases of AIS. Clinical data for 31 
index patients with AIS (P1-P31) and three affected 
family members (A2, A6 and A25) are summarised 
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in Table 1. 
Several methods of grading the clinical forms of 
AIS are in use. One method devised by Prader 
classifies the genital phenotype on a grade of 1-7 in 
order of increasingly female phenotype and thus 
severity of AIS3. A more recent grading system, 
devised by Ahmed et al.21, was used to assess the 
phenotype of the patients reported herein. In this 
system specific clinical features are assessed result-
ing in a masculinisation score, a score of 12 
representing normal male development (see Table 
1). 
An XY karyotype was recorded in all 34 
affected patients. All patients have had endocrine 
investigations demonstrating normal testosterone 
production. 
Patients P2, P6 and PI0 had a family history of 
AIS. No other patients had a family history of AIS 
at the time of testing. In many cases family 
members were not available for testing. All genetic 
results from available family members and carriers 
are described in the Results section. 
Genomic DNA PCR sequencing 
Genomic DNA was extracted from whole blood 
(peripheral leukocytes)28 and subjected to PCR 
analysis. AR gene specific primers used for PCR 
amplification and DNA sequencing are described in 
Table 2. 
Exons B-Η of the AR gene were PCR amplified 
and sequenced; regions amplified included exonic 
sequences, splice sites and the 3'-untranslated 
region (UTR). If a deleterious mutation was found, 
the Gin repeat region in exon A was PCR amplified 
and sequenced, followed by reporting of results. 
For patients tested more recently the method was 
modified so that the exon A Gly repeat region was 
also PCR amplified and sequenced, in addition to 
the Gin repeat region. 
If no deleterious mutation could be detected in 
exons B-Η, then the entire coding region of exon A 
was amplified and sequenced, including Gln/Gly 
repeat regions, splice sites and the proximal pro-
moter region (-160 base pairs [bp] to the tran-
scription start site [TSS]). 
Exon B-Η PCRs were performed using TaqFl 
DNA Polymerase System (Cat#TAQ-l, Fisher 
Biotec, Sydney, Australia). Exon B-Η PCRs were 
sequenced using the same primers as used for PCR 
amplification. Exon A PCRs were performed using 
GC-Rich PCR System (Cat#2140306, Roche/ 
Boeringer Mannheim, Mannheim, Germany). Exon 
A PCRs were sequenced using the same primers as 
used for PCR amplification in addition to nested 
sequencing primers. See Table 2 for details of PCR 
conditions. All PCR reactions contained 0.2 μΜ 
nucleotide mix and 0.5 μΜ of each primer. 
PCR products were purified with High Pure 
PCR Product Purification Kit (Cat#l 732668 
Roche/Boeringer Mannheim, Mannheim, Germany), 
then sequenced using Big-Dye-Terminator-Cycle-
Sequencing-Ready-Reaction (Cat#4303149, Applied 
Biosystems, Scoresby, Victoria, Australia). Ana-
lysis was performed at the Griffith University 
Sequencing Facility (Griffith University, Nathan, 
QLD, Australia). All sequences were compared to 
consensus sequences for AR genomic and mRNA 
sequences (Genbank Refseq NM000044). 
All identified mutations were confirmed by 
repeating the entire procedure (DNA extraction, 
PCR and sequencing) on a second blood sample 
obtained from the patient. 
RT-PCR sequencing 
In three patients genital skin fibroblasts were 
available for tissue culture. Total RNA was 
extracted from cultured genital skin fibroblasts 
using RNeasy Mini Kit (Cat#74104, Promega, 
Sydney, Australia). Reverse transcription was 
carried out using the gene specific primer AR-H-
3202-21-AS located in the 3 - U T R of the AR 
mRNA transcript. Reverse transcription was per-
formed using the Reverse Transcription System 
(Cat#A3500, Promega, Sydney, Australia) accor-
ding to the manufacturer's instructions. PCR 
amplification of cDNA was performed as described 
above using TaqFl DNA Polymerase System (Cat 
#TAQ-1, Fisher Biotec). See Table 2 for details of 
primers and PCR conditions. The region of cDNA 
analysed included the 3' end of exon A, exons B-H 
and the 3'-UTR. PCR products were purified and 
sequenced as described above using the same 
primers as used for PCR amplification in addition 
to nested sequencing primers. 
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TABLE 2 
Oligonucleotide primers and PCR conditions 
Exons Primer label * Sequence PCR 
product 
size 
(bp) 
PCR 
annealing 
temp 
(VC) 
PCR cycling times 
(sec ["]) 
94°C; jr°C; 72°C 
χ 34 cycles 
PCR PCR 
[Mg2*] [GC-rich 
(mM) resn. soln.] 
(M) 
fitnamte d n a p c r m a l i f l a t t a 
A AR-A-172-25-S 
AR-A-1218-20-AS 
A AR-A-953-24-S 
AR-A-1708-23-AS 
A AR-A-I410-27-S 
AR-A-2037-23-AS 
A AR-A-172-25-S 
AR-A-726-21-AS 
Β AR-B-(IntronA)-24-S 
AR-B-(IntronB)-26-AS 
C AR-C-(IntronB)-23-S 
AR-C-(lntronC)-25-AS 
D AR-D-(IntronC)-23-S 
AR-D-(IntronD)-23-AS 
Ε AR-E-(IntronD)-25-S 
AR-E-{IntronE)-21 -AS 
F AR-F-(IntronE)-25-S 
AR-F-{IntronF)-23-AS 
G AR-G-(lntronF)-22-S 
AR-G-(IntronG)-24-AS 
Η AR-H-(IntronG)-24-S 
AR-H-3202-21 -AS 
cDNA PCR amplification 
A t o G AR-A-1778-20-S 
AR-G-2894-21 -AS 
C to Η AR-C-22I8-25-S 
AR-H-3202-21-AS 
Additional sequencing primers 
GCACGAGACTTTGAGGCTGTCAGAG 
CCAATGGGGCACAAGGAGTG 
GGAAGCAGTATCCGAAGGCAGCAG 
CCACACGGTCCATACAACTGGCC 
GCACTGGACGAGGCAGCTGCGTACCAG 
CCAGAACACAGAGTGACTCTGCC 
GCACGAGACTTTGAGGCTGTCAGAG 
CCAGGGCCGACTGCGGCTGTG 
GCCTGCAGGTTAATGCTGAAGACC 
CCTAAGTTATTTGATAGGGCCTTGCC 
GTTTGGTGCCATACTCTGTCCAC 
CTGATGGCCACGTTGCCTATGAAAG 
GGAGTTTAGAGTCTGTGACCAGG 
GATCCCCCTTATCTCATGCTCCC 
CAACCCGTCAGTACCCAGACTGACC 
GCTTCACTGTCACCCCATCAC 
CTCTGGGCTTATTGGTAAACTTCCC 
GTCCAGGAGCTGGCTTTTCCCTA 
CTTGGTGCTTTGTCTAATGCTC 
CTCTATCAGGCTGTTCTCCCTGAT 
GAGGCCACCTCCTTGTCAACCCTG 
GGAGTAGTGCAGAGTTATAAC 
CGAGGCGGGAGCTGTAGCCC 
GCATGCAATGATACGATCGAG 
GTTATGAAGCAGGGATGACTCTGGG 
GGAGTAGTGCAGAGTTATAAC 
A AR-A-431-24-S CCAGAATCTGTTCCAGAGCGTGCG 
A AR-A-533-26-AS CAGCAGCAGCAAACTGGCGCCGGGAG 
A AR-A-623-21-S GCAGCAGGGTGAGGATGGTTC 
A AR-A-1153-19-S GATTGCATGTACGCCCCAC 
A AR-A-1469-22-AS CAGAGCCAGTGGAAAGTTGTAG 
A AR-A-1598-23-S GCATGGCGCGGGTGCAGCGGGAC 
A AR-A-1798-20-S CCTACGGCTACACTCGGCCC 
Β AR-B-2033-20-S GACCTGCCTGATCTGTGGAG 
C AR-C-2244-25-AS CCCAGAGTCATCCCTGCTTCATAAC 
D AR-D-2244-20-S GCCCGGAAGCTGAAGAAACT 
Ε AR-E-2559-21-S CAGATGGCTGTCATTCAGTAC 
Ε AR-E-2675-23-AS CATTGAAAACCAGATCAGGGGCG 
F AR-F-2753-20-S CCAAATCACCCCCCAGGAAT 
Η AR-H-3177-20-AS GAAGACATCTGAAAGGGGGC 
1046 
755 
627 
554 
379 
413 
456 
284 
294 
276 
289 
1116 
984 
60 
65 
60 
70 
60 
60 
60 
60 
60 
60 
60 
55 
55 
60"; 60"; 60" 
60"; 60"; 60" 
60"; 60"; 60" 
60"; 60"; 60" 
60"; 60"; 60" 
30"; 60"; 60"" 
30"; 60"; 60" 
60"; 60"; 60"" 
60"; 60"; 60" 
60"; 60"; 60" 
60"; 60"; 60" 
2 
2 
2 
2 
1.5 
2 
2 
1.5 
1.5 
1.5 
1.5 
60"; 60"; 60" 1.5 
60"; 60"; 60" 1.5 
1 
1 
1.5 
0.5 
Details of PCR amplifications and sequences of oligonucleotide primers used for PCR/DNA sequencing. Some primers are listed 
more than once. 
* Primer labels: e.g. AR-B-(2033)-20-S, gene-exon-(position relative to published sequence)-size [bp]-antisense [AS] or sense [S]. 
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM 
Brought to you by | University of Queensland - UQ Library
Authenticated
Download Date | 10/27/15 5:32 AM
ANDROGEN RECEPTOR MUTATIONS IN AUSTRALASIAN PATIENTS WITH AIS 899 
PCR-RFLP 
PCR products containing the region of interest 
were amplified from patient, carrier and/or wildtype 
DNA as described above. After purification PCR 
products were digested with Apal or Mwol. Diges-
tion products were visualised on 2.5% agarose gel. 
RESULTS 
Clinical and genetic data for 31 patients with 
AIS, PI to P31, and three affected family members, 
A2, A6 and A25, are summarised in Table 1. 
Further details of genotyping results and carrier 
testing are presented in Table 3. Mutations are 
reported in a manner consistent with the AR 
mutations database available online, the McGill 
database29. All nucleotide and amino acid number-
ing of reported mutations is identical to the McGill 
database 9. Figure 1 shows a sequencing chromato-
gram of the one of the novel mutations detected in 
this study. 
CAIS patient PI was found to have a novel 
deletion at nucleotide 858, N858delG (codon 
Glyl66, exon A). This deletion leads to a premature 
stop at codon 172. A novel deletion N2676del 
GAGT (codon Glu772, exon E) resulting in a stop 
at codon 787 was found in CAIS patients P2 and 
A2. Both of these frameshift mutations would 
result in inactivation of AR protein. CAIS patient 
P3 was found to have a novel insertion of a cysteine 
residue in the first zinc finger of the AR DNA-
binding domain (DBD) (N2045_2047dupCTG). A 
novel amino acid substitution (Arg760Ser) in the 
AR ligand binding domain (LBD) was found in 
PAIS patient P4. 
CAIS patient P5 was found to have the mutation 
Pro892Leu, previously reported in CAIS29·30. A 
similar CAIS mutation Pro892Ser is associated 
with reduced AR binding capacity and a diminished 
AR transactivation property 1. 
CAIS patients P6 and A6 were each found to 
have the mutation Arg752Gln. This mutation is 
located in the AR LBD, and has been previously 
reported in CAIS29'32. The Arg752Gln mutation re-
sults in diminished androgen-binding capacity29'32. 
PAIS patient P7 was found to have the mutation 
Gly568Trp, previously reported in PAIS29,33. This 
Fig. 1: N2045-2047dupCTG mutation. Lower panel: Sequencing chromatogram depicting hemizygous 2045_2047dupCTG 
mutation in patient P3. The CTG duplication is indicated by the black box. Upper panel: Sequencing chromatogram 
depicting wildtype sequence. 
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TABLE 3 
Deta i l s o f geno typ ing resul ts and carr ier t es t ing fo r pat ients PI to P9 and a f f ec t ed fami ly m e m b e r s A 2 and A 6 
Pat Hemizygous AR gene AR gene mutation AIS AR AR Carrier/family testing 
ID mutation Protein/amino acidT pheno- functional Exon 
NucleotideT type domain 
PI 
P2 
N858delG 
N2676delGAGT 
Frameshift, 
stop at codon 172 
Frameshift, 
stop at codon 787 
CAIS Deletion of A 
TAD, DBD, 
LBD 
CAIS Deletion Ε 
of LBD 
RFLP analysis using Apal 
showed that mother of PI is 
heterozygous for mutation 
Sequencing analysis showed that 
mother of P2 is heterozygous for 
mutation 
A2 N2676delGAGT 
P3 N2045_2047dupCTG 
P4 N2642G-T 
Frameshift, 
stop at codon 787 
Insertion C 
after C562 
R760S 
CAIS Deletion 
of LBD 
CAIS DBD 
PAIS LBD Ε 
See pedigree (Fig. 2) 
RFLP analysis using Mwol 
showed that mother of P3 is 
heterozygous for mutation 
Sequencing analysis showed that 
mother of P4 is heterozygous for 
mutation 
P5 N3037C-T P892L CAIS LBD Η Sequencing analysis showed that 
sister of P5 does not have the 
mutation 
P6 N2617G-A R752Q CAIS LBD Sequencing analysis showed that 
mother of P6 is heterozygous for 
mutation 
A6 
P7 
N2617G-A 
N2064G-T 
R752Q 
G568W 
CAIS LBD Ε 
PAIS DBD Β 
See pedigree (Fig. 3) 
Sequencing analysis showed that 
mother of P7 is heterozygous for 
mutation 
P8 N2973A-G R871G PAIS LBD Η Sequencing analysis showed that 
sister of P8 does not have the 
mutation 
P9 N2074A-G Y571C CAIS DBD Β Sequencing analysis showed that 
mother of P9 is heterozygous for 
mutation 
The five AR gene mutations in bold are novel mutations. 
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mutation has an effect on transrepression of 
androgen-induced activation by activator protein-1 
(AP-1), a transcription factor known to modulate 
AR action34. Gly568Trp may result in disruption of 
cross talk between the androgen signalling pathway 
and other growth factor pathways. 
The mutation Arg871Gly was identified in PAIS 
patient P8. This mutation has been previously 
reported in PAIS29,35. Shkolny et al*5 report that 
the Arg871Gly mutation results in discordant 
androgen binding in transfected COS-1 cells and in 
genital skin fibroblasts from the patient. 
CAIS patient P9 was found to have the mutation 
Tyr571Cvs which has previously been reported in 
CAIS2 . This mutation is located in the first zinc 
finger of the AR DBD. The Tyr571Cys mutation 
may affect the 3-dimensional structure of the DBD 
zinc finger leading to altered DNA-binding activity 
of the AR protein. 
Sequencing of the entire AR gene exons A-H 
failed to reveal any deleterious mutations in 
patients P10 to P31 or family member A25. 
In three of the 34 patients and family members, 
genital skin fibroblasts were available for tissue 
culture. RT-PCR on genital skin fibroblast tissue 
culture from patients P21, P23 and P24 showed that 
exons B-Η of AR cDNA were intact. 
In summary, patients PI, P2 and A2 have novel 
AR mutations which result in inactivation of the AR 
protein. Patients P5, P6, A6, P7, P8 and P9 have 
previously reported deleterious AR gene mutations 
known to be associated with the AIS phenotype. 
Thus genotyping has provided a clear explanation 
of phenotype for these seven patients and two 
affected family members. Patients P3 and P4 have 
novel AR mutations of uncertain functional effect 
on AR protein. For these two patients further 
studies on the effect of the novel mutations will be 
required to account for the AIS phenotype. 
Pedigree analysis for patient P2 
Figure 2 shows the pedigree analysis of the 
N2676delGAGT mutation and polymorphic markers 
(exon A Gin repeat). All family members tested 
were screened for both the N2676delGAGT 
mutation and exon A polymorphic markers (exon A 
Gin repeat). Patient A2 is the 46,XY aunt of patient 
P2. The mother of P2 is a heterozygous carrier of 
the mutation. Another sibling of A2 has an AIS 
affected child; these family members were un-
available for testing. The maternal grandmother of 
P2 is deceased, but the presence of the mutation in 
more than one of her progeny suggests that she may 
have carried the N2676delGAGT mutation. 
Pedigree analysis for patient P6 
Figure 3 shows the pedigree analysis of patients 
P6 and A6. All family members tested were 
screened for both the Arg752Gln mutation and 
exon A polymorphic markers (exon A Gin repeat). 
The mother of P6 is a heterozygous carrier for the 
Arg752Gln mutation. The sister of P6 was shown 
to be an unaffected carrier who transmitted the 
mutation to her 46,XY daughter, CAIS patient A6. 
The absence of the Arg752Gln mutation in the aunt 
and grandmother of patient P6 indicates that the 
mother of P6 had acquired the mutation de novo. 
Mutations of the AR gene occurring de novo have 
been shown to occur at a rate of 26.7% in AIS37. 
Gln/Gly repeats 
For all patients tested the number of AR Gin 
(CAG) and Gly (GGN) repeats were within the 
normal range. However, several patients have CAG 
or GGN repeat lengths that were at the upper or 
lower ends of the normal ranges (Table 1). For 
most of the patients the number of CAG and GGN 
repeats are similar and differ by a value of 3 or less. 
However, for several of the PAIS/CAIS patients 
with no deleterious mutation the number of CAG 
and GGN repeats differs by a value of 5 or more 
(patients PI0 to Ρ16). Patients P10 and PI 1 have a 
difference of 19 and 15, respectively. 
DISCUSSION 
We detected AR gene defects in 66.7% (6/9) of 
non-related CAIS patients, comparable to previous 
reports of 83% (57/69)27. The rate of detection of 
AR gene defects in PAIS has been reported as 28% 
(12/43)27. The lower detection rate for PAIS re-
ported here of 13.6% (3/22) may be due to the 
small sample number. 
Of the nine AR gene mutations identified in this 
study, five are previously identified AR mutations. 
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AR ALLELES 
N2676DelnGAGT 
21 Gin Ex A 
• 
#Gln 
repeats 
23I ExonA 
Not tested, Unaffected 
Not tested, 
Known affected / 
Suspected Carriers 
ό 
to 
τ Ο • — t ) 
Ο 3 2» € δ < 
WA2 
"P2 
Fig. 2: Pedigree for N2676delGAGT mutation. Pedigree for family of patients P2 and A2. P2 and A2 both have CAIS and are 
hemizygous for the N2676delGAGT mutation. Pedigree analysis demonstrates that the deceased mother of A2 may have 
carried the mutation. A third affected patient is indicated in the pedigree, although this patient and her mother have not 
been tested for the mutation. (The marker used for pedigree analysis is the polymorphic AR Gin repeat region, the results 
for which are indicated in the pedigree.) 
AR ALLELES 
Arg752Gln 
20Gln ExA 
#Gln 
y repeats 
ExonA 
Not tested 
)Δ rn 
- t o - ι i 
Ο 
P 6 
I A 6 
Fig. 3: Pedigree for Arg752Gln mutation. Pedigree for family of patients P6 and A6. Patterns P6 and A6 both have CAIS and 
are hemizygous for the Arg752Gln mutation. Pedigree analysis demonstrates tnat the mutation occurred de novo in the 
mother of P6. The mothers of P6 and A6 are both heterozygous unaffected carriers for the Arg752Gln mutation. 
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two are novel mutations known to lead to in-
activation of AR, and two are novel mutations of 
uncertain effect on AR function. The four novel 
mutations are discussed in detail. 
The N858delG mutation found in PI has not 
been previously reported29. The deletion results in a 
frameshift that introduces a premature stop at 
codon 172. Other mutations have been described 
resulting in a stop at codon 172, and all but one are 
associated with CAIS29. One patient was reported 
as having PAIS, but it was shown that the PAIS 
phenotype was a result of somatic mosaicism38. 
The AR protein has been reported to have two 
isoforms, AR-A and AR-B. AR-A is an N-
terminally truncated version of the full-length AR-
EI isoform. AR-A retains the steroid and DNA 
binding domains, but lacks a significant portion of 
the amino terminal transactivation region of AR-B. 
Transfection experiments have shown subtle diffe-
rences in function between the AR-A and AR-B 
isoforms on selected response elements39. 
Wilson and McPhaul40 showed that the AR-A 
isoform co-migrates with an expressed fragment 
that initiates from a second methionine at AR 
residue 189. It has been suggested that the AR-A 
isoform could arise in vivo as a result of translation 
from an internal start site at Metl8 940'41. In 
addition, Gao and McPhaul39 report that the nucleo-
tide sequence surrounding Met 189 would cause it 
to be used inefficiently as a translation initiation 
site. In vitro proteolysis results of Gregory et al A1 
raise an alternative theory, i.e. that AR-A arises as a 
proteolytic fragment of full length AR-B. They 
suggest that observations of an AR-A isoform in 
tissue extracts and cell culture is due to proteolysis 
of AR-B during protein extraction. Thus the AR-A 
isoform is generated in vivo as a result of proteo-
lysis of AR-B, rather than from initiation of trans-
lation at Met 189. Further, Gregory et α/.42 propose 
that AR-A has no functional role in vivo. 
Any AR mutations leading to a premature stop 
5' of codon Met 189, such as the N858delG muta-
tion reported here, would result in an inactive 3'-
truncated version of AR-B. The severe phenotype 
of CAIS in these cases29 suggests that AR-A is 
either not present or not functional in these patients, 
supporting the evidence of Gregory et al.42 that ΑΡ-
Α is produced by proteolysis and not from trans-
lation at Metl89. Genital skin fibroblasts from two 
patients with a premature stop 5' of codon Met 189, 
Gln60Stop41, were observed to have residual andro-
gen binding activity. This could be explained by 
translation of a truncated AR isoform from a 
putative start site at Met507. An AR isoform 
arising from Met507 would retain the ligand 
binding domain but would be inactive due to 
absence of the entire N-terminal domain. 
The N2676delGAGT mutation found in CAIS 
patients P2 and A2 has not been previously re-
ported. Pedigree analysis of the family of P2 shows 
that two of her sisters do not carry the N2676 
delGAGT mutation (Fig. 2), clearly demonstrating 
the value of AR genotyping. The N2676delGAGT 
mutation results in a frameshift leading to a pre-
mature stop at codon 787. This would result in the 
loss of the ligand binding domain of the AR 
protein. Various mutations in the AR gene have 
been described leading to a premature stop at codon 
787. A CAIS patient with a 13-bp deletion in exon 
D of the AR gene has been described, leading to a 
frameshift and a premature stop at codon 78729'43. 
This 13-bp deletion was reproduced in androgen 
receptor wildtype cDNA and transfected into mam-
malian cells. Western blot analysis demonstrated a 
smaller androgen receptor of 94 kDa for the 
transfected mutated cDNA instead of 110 kDa43. A 
lack of androgen binding was demonstrated in the 
mutated transfected cells. It was shown that the 
mutant could bind target DNA but was unable to 
transactivate a reporter gene43. A CAIS patient with 
a substitution leading to a stop at codon 786 has 
also been characterised; in vitro androgen binding 
studies report a Bmax of zero, indicating that this 
mutant receptor is unable to bind ligand29'44. 
Various reports describe CAIS patients with a 1-bp 
deletion in codon Pro766 of the AR gene27'29,44"4®. 
This 1-bp deletion in Pro766 would result in a 
frameshift leading to a premature stop at codon 787 
(erroneously reported as leading to a stop in codon 
80729). 
The N2045_2047dupCTG mutation found in 
CAIS patient P3 has not been previously reported. 
This mutation results in the insertion of a cysteine 
in the first zinc finger of the highly conserved AR 
DNA-binding domain between amino acids 562 
and 563 (Fig. 4). The mutation is adjacent to one of 
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four highly conserved cysteine residues which are 
required to bind a zinc ion. Binding of metal ion is 
essential for stabilisation of the active conformation 
of the domain, enabling the AR to interact with 
target DNA47. There is also a conserved cysteine 
residue at position 569 in the DBD which is likely 
to be involved in stabilizing the DBD but not in 
binding of the metal ion (Fig. 4)48. The additional 
cysteine residue may affect the 3-dimensional 
structure of the zinc finger causing inefficient 
binding of the mutant AR to target DNA sequences 
due to decreased stability, or may reduce the 
capacity of the bound receptor to activate tran-
scription. This is the first report of amino acid 
duplication in the AR. Future work may involve 
in vitro studies to elucidate the role of the 
N2045_2047dupCTG mutation in AIS. 
The Arg760Ser mutation found in PAIS patient 
P4 has not been previously reported. The arginine 
residue at position 760 is highly conserved in AR 
from various species, and is located in the highly 
conserved LBD of the AR. The Arg760 residue is 
located in LoopH4H5 in the predicted 2-
dimensional structure of the AR49. The residue is 
located outside of the ligand-binding pocket and 
does not interact with the bound ligand directly5 , 
but is involved in maintaining the structure of the 
ligand-binding pocket. The region surrounding the 
Arg760Ser mutation is a known mutational cluster 
site of the AR36. The mutational cluster is located 
between codons 728 and 774 and is homologous to 
a region in the human thyroid receptor which is a 
known cluster site for mutations that cause thyroid 
hormone resistance". This would indicate that this 
region plays an important role in the interaction 
between hormone and receptor. The conversion of 
the large basic, positively charged arginine residue 
at position 760 to the small, neutral, hydrophilic 
serine residue would be likely to have an effect on 
the 3-dimensional structure of the AR. 
Patients P10 and P l l had no deleterious AR 
mutation but were found to have a large difference 
between the number of CAG and GGN repeats 
(Table I). Although highly speculative, it is pos-
sible that this Gln/Gly repeat imbalance has a 
functional consequence. Long Gin repeats are 
associated with undermasculinisation, male in-
fertility and defective spermatogenesis8,9,14"17. Short 
Gin repeats are associated with prostate cancer5'19. 
Expansion of the Gin repeat is associated with 
reduced expression of AR in COS cells52. Short Gly 
repeats are associated with benign prostatic hyper-
plasia18 and prostate cancer5,19·22,24· 3 and long Gly 
repeats with endometrial cancer21. Contraction of 
the Gly repeat led to increased levels of AR protein 
in DU 145 human prostate cancer cells54. 
The mechanism by which AR function may be 
affected by Gln/Gly repeat length can only be 
speculated upon. The Gln/Gly repeats are located in 
a region of AR protein known to bind to CO-
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regulators. This region is also important for intra 
molecular interaction between the N- and C-
terminal ends of AR induced by ligand binding55"58. 
It was demonstrated that a normal N/C interaction 
occurs only for AR protein with 16-29 Gin 
repeats59. Recent in vitro work by Werner et al.60, 
indicating that the combination of a short Gly 
repeat with a long Gin repeat influenced the effect 
of a mutation within the ligand binding domain, 
Ala645Asp, supports our hypothesis of a functional 
relationship between the AR polyglycine and 
polyglutamine segments. 
The Gln/Gly repeat region is capable of forming 
stable RNA stem-loop structures, and the stability 
of these structures increases with repeat number54,6. 
Some cellular RNA-binding regulatory proteins 
bind to stem-loop motifs in target RNA82. It is 
possible that variation in the repeat length of AR 
mRNA molecules has an effect on the binding of 
RNA regulatory proteins, resulting in altered 
mRNA processing. 
One hundred percent (9/9) of the mutations 
identified in this study were in exons B-Η. The 
majority of AR gene mutations in AIS are located in 
exons B-Η29. Thus our genotyping strategy is 
successful, i.e. to first sequence only exons B-H 
and then to test exon A if no deleterious mutation is 
found. No deleterious AR gene mutations were 
found in patients P10 to P31. The cause of 
abnormal virilisation in this significant proportion 
of patients remains unclear, as has been found in 
other studies27. It is possible that the AIS phenotype 
may be due to mutations in the AR promoter or in 
other genes involved in the androgen-response 
pathway. The next step in genotyping our patient 
cohort would be to examine the distal 5-promoter 
regions of the AR gene, at least in the 3/9 CAIS 
patients found not to have a mutation. Mutations in 
the promoter may affect expression of the AR gene 
and/or binding to regulatory factors. In addition, 
genital skin biopsy from patients and subsequent 
cDNA analysis and/or expression studies could be 
undertaken. DNA analysis in AIS is an invaluable 
tool providing insights into the relationship be-
tween genital phenotype and AR mutation. In 
addition, it is vital clinically in terms of accurate 
diagnosis, carrier detection, pedigree analysis and 
genetic counselling. 
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